Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
otamixaban XRP0673 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Mild impairment | EXPERIMENTAL | Patients with mild hepatic impairment |
| Moderate impairment | EXPERIMENTAL | Patients with moderate impairment |
| Healthy subjects | EXPERIMENTAL | Matched healthy subjects |
| Name | Type | Description |
|---|---|---|
| otamixaban XRP0673 | DRUG | Pharmaceutical form: solution for injection Route of administration: intravenous |
Inclusion criteria: \- Subjects with hepatic impairment: * Body weight between 50.0 kg and 115.0 kg inclusive if male, between 40.0 kg and 100.0 kg inclusive if female, Body Mass Index between 18.0 and 34.9 kg/m2 inclusive * Stable chronic liver disease assessed by medical history, physical examin...
Otamixaban XRP0673 is an investigational small molecule being studied for use in patients with mild and moderate hepatic impairment. It is being developed by Sanofi (SNY) and is currently in Phase 1 clinical development. The drug is not approved and remains under investigation.
Otamixaban XRP0673 is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 1 clinical development for hepatic impairment.
Otamixaban XRP0673 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study in patients with hepatic impairment has been completed.
Otamixaban XRP0673 has one completed Phase 1 clinical trial, identified as NCT01126086. This study evaluated the pharmacokinetics, pharmacodynamics, and tolerability of otamixaban in patients with mild and moderate hepatic impairment. The trial enrolled 25 participants in the United States.
Yes, otamixaban XRP0673 is also known as XRP0673. Both names refer to the same investigational drug being developed by Sanofi for hepatic impairment. The drug is currently in Phase 1 clinical development.